Almost certainly one of the first issues to be discussed at the first meeting of the biosimilar working group including the two key industry associations will be the status of so-called 'clones'.

New Stories
-
AbbVie: Not yet on Venclexta but future is positive
April 23, 2018 - - Latest News -
A proud industry committed to doing the right thing
April 23, 2018 - - Latest News -
March PBAC outcomes
April 23, 2018 - - Latest News -
GBMA confirms biosimilar education grant
April 23, 2018 - - Latest News -
Mayne officially opens US facility
April 20, 2018 - - Latest News -
The question is how and why now?
April 20, 2018 - - Latest News -
New report show rebates average 44% in New Zealand
April 20, 2018 - - Latest News